Logo image of BSGM

BIOSIG TECHNOLOGIES INC (BSGM) Stock Fundamental Analysis

NASDAQ:BSGM - US09073N3008 - Common Stock

4.219 USD
-0.19 (-4.33%)
Last: 9/9/2025, 1:21:58 PM
Fundamental Rating

0

BSGM gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of BSGM have multiple concerns. BSGM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BSGM has reported negative net income.
In the past year BSGM has reported a negative cash flow from operations.
In the past 5 years BSGM always reported negative net income.
In the past 5 years BSGM always reported negative operating cash flow.
BSGM Yearly Net Income VS EBIT VS OCF VS FCFBSGM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

BSGM has a Return On Assets (-23.52%) which is in line with its industry peers.
Industry RankSector Rank
ROA -23.52%
ROE N/A
ROIC N/A
ROA(3y)-1196.25%
ROA(5y)-793.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BSGM Yearly ROA, ROE, ROICBSGM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BSGM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BSGM Yearly Profit, Operating, Gross MarginsBSGM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

0

2. Health

2.1 Basic Checks

BSGM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BSGM has more shares outstanding
The number of shares outstanding for BSGM has been increased compared to 5 years ago.
BSGM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BSGM Yearly Shares OutstandingBSGM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
BSGM Yearly Total Debt VS Total AssetsBSGM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

BSGM has an Altman-Z score of -2.45. This is a bad value and indicates that BSGM is not financially healthy and even has some risk of bankruptcy.
BSGM has a Altman-Z score of -2.45. This is in the lower half of the industry: BSGM underperforms 62.11% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.45
ROIC/WACCN/A
WACC8.74%
BSGM Yearly LT Debt VS Equity VS FCFBSGM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

BSGM has a Current Ratio of 0.03. This is a bad value and indicates that BSGM is not financially healthy enough and could expect problems in meeting its short term obligations.
BSGM has a worse Current ratio (0.03) than 98.42% of its industry peers.
A Quick Ratio of 0.03 indicates that BSGM may have some problems paying its short term obligations.
The Quick ratio of BSGM (0.03) is worse than 98.42% of its industry peers.
Industry RankSector Rank
Current Ratio 0.03
Quick Ratio 0.03
BSGM Yearly Current Assets VS Current LiabilitesBSGM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

1

3. Growth

3.1 Past

BSGM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 80.81%, which is quite impressive.
Looking at the last year, BSGM shows a very negative growth in Revenue. The Revenue has decreased by -72.97% in the last year.
The Revenue for BSGM have been decreasing by -55.07% on average. This is quite bad
EPS 1Y (TTM)80.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-136.67%
Revenue 1Y (TTM)-72.97%
Revenue growth 3Y-55.07%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

BSGM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.64% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y68.52%
EPS Next 2Y33.64%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BSGM Yearly Revenue VS EstimatesBSGM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
BSGM Yearly EPS VS EstimatesBSGM Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2020 2021 2022 2023 2024 2025 2026 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BSGM. In the last year negative earnings were reported.
Also next year BSGM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BSGM Price Earnings VS Forward Price EarningsBSGM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BSGM Per share dataBSGM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as BSGM's earnings are expected to grow with 33.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.64%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BSGM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOSIG TECHNOLOGIES INC

NASDAQ:BSGM (9/9/2025, 1:21:58 PM)

4.219

-0.19 (-4.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12
Earnings (Next)11-12 2025-11-12
Inst Owners26.83%
Inst Owner Change38.64%
Ins Owners20.16%
Ins Owner Change10.21%
Market Cap608.97M
Analysts82.86
Price Target10.2 (141.76%)
Short Float %7.28%
Short Ratio1.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)300%
EPS NQ rev (1m)0%
EPS NQ rev (3m)77.78%
EPS NY rev (1m)0%
EPS NY rev (3m)-25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 60897.05
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0
BVpS-0.02
TBVpS-0.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.52%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1196.25%
ROA(5y)-793.27%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.03
Quick Ratio 0.03
Altman-Z -2.45
F-Score3
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)36.29%
Cap/Depr(5y)95.03%
Cap/Sales(3y)364.03%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-136.67%
EPS Next Y68.52%
EPS Next 2Y33.64%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-72.97%
Revenue growth 3Y-55.07%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-45.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y78.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.81%
OCF growth 3YN/A
OCF growth 5YN/A